#USA #Burlington #oncology #Labcorp #Plasma Complete

Labcorp Unveils Cutting-Edge Liquid Biopsy Test

In a major advancement for cancer treatment, Labcorp (NYSE: LH), a pioneer in innovative laboratory services, recently announced the clinical rollout of its new liquid biopsy test, Labcorp® Plasma Complete™. This groundbreaking tool is designed specifically for patients with advanced solid tumors and offers oncologists unparalleled genomic profiling capabilities with just a simple blood draw.

Labcorp Plasma Complete utilizes advanced technology to analyze circulating tumor DNA (ctDNA). This method allows healthcare providers to glean vital genomic insights that can significantly influence personalized treatment strategies. According to Dr. Shakti Ramkissoon, vice president and medical lead for oncology at Labcorp, "This test provides powerful insights that enable targeted treatment decisions, even when tissue-based testing isn't a viable option."

Key Features of Labcorp Plasma Complete

The newly launched test detects genomic alterations within ctDNA across 521 different genes, providing a comprehensive overview of a patient's tumor profile. This includes the identification of single nucleotide variants (SNVs), insertions and deletions (InDels), gene amplifications, and even associated microsatellite instability (MSI) status. By covering both established and emerging biomarkers linked to FDA-approved therapies, Labcorp Plasma Complete supplies oncologists with essential information needed to tailor treatments more precisely for each patient.

Additionally, the test's clear and well-organized clinical reports are supported by robust bioinformatics. These features not only simplify the interpretation of complex genomic data but also significantly lessen the workload for oncologists, facilitating smoother clinical workflows. This integration with Labcorp's extensive cancer diagnostic offerings helps to streamline treatment decisions across various stages of cancer care, from diagnosis through treatment.

Clinical Validation and Performance

The Labcorp Plasma Complete test has undergone rigorous validation procedures, affirming its accuracy and reliability as published in the Journal of Molecular Diagnostics. The test can detect mutations with a variant allele frequency as low as 0.1%, boasting a specificity exceeding 99.99%. Such precision is crucial for recognizing tumor-specific biomarkers tied to disease progression and resistance, ultimately giving oncologists invaluable confidence in their treatment plans.

Notably, Labcorp Plasma Complete remains accessible for biopharmaceutical research while also expanding its use in direct clinical patient care, solidifying Labcorp's stance as a leader in comprehensive laboratory services. The test demonstrates Labcorp's commitment to evolving personalized medicine and enhancing patient outcomes in oncology.

About Labcorp

Labcorp is recognized as an innovator in laboratory services, helping physicians, hospitals, and patients worldwide make informed health decisions. With an impressive workforce approaching 70,000 and a presence in nearly 100 countries, Labcorp has played a pivotal role in the approval of over 75% of new drugs and therapeutic products by the FDA in the past year, while conducting more than 700 million tests annually.

Conclusion

The introduction of Labcorp Plasma Complete marks a significant leap forward in the fight against cancer, providing oncologists with vital tools to customize treatment plans based on genetic information. This test not only enhances the capabilities of cancer care providers but also holds the promise of improving outcomes for patients battleing advanced solid tumors. To learn more about this innovative test, visit Labcorp Plasma Complete.